139 related articles for article (PubMed ID: 37997097)
1. The impact of risk stratification by polygenic risk and age on breast cancer screening in women aged 40-49 years: a modelling study.
Huntley C; Torr B; Sud A; Houlston RS; Hingorani AD; Jones ME; Turnbull C
Lancet; 2023 Nov; 402 Suppl 1():S54. PubMed ID: 37997097
[TBL] [Abstract][Full Text] [Related]
2. Utility of polygenic risk scores in UK cancer screening: a modelling analysis.
Huntley C; Torr B; Sud A; Rowlands CF; Way R; Snape K; Hanson H; Swanton C; Broggio J; Lucassen A; McCartney M; Houlston RS; Hingorani AD; Jones ME; Turnbull C
Lancet Oncol; 2023 Jun; 24(6):658-668. PubMed ID: 37178708
[TBL] [Abstract][Full Text] [Related]
3. Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
van den Broek JJ; Schechter CB; van Ravesteyn NT; Janssens ACJW; Wolfson MC; Trentham-Dietz A; Simard J; Easton DF; Mandelblatt JS; Kraft P; de Koning HJ
J Natl Cancer Inst; 2021 Apr; 113(4):434-442. PubMed ID: 32853342
[TBL] [Abstract][Full Text] [Related]
4. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
Mandelblatt JS; Stout NK; Schechter CB; van den Broek JJ; Miglioretti DL; Krapcho M; Trentham-Dietz A; Munoz D; Lee SJ; Berry DA; van Ravesteyn NT; Alagoz O; Kerlikowske K; Tosteson AN; Near AM; Hoeffken A; Chang Y; Heijnsdijk EA; Chisholm G; Huang X; Huang H; Ergun MA; Gangnon R; Sprague BL; Plevritis S; Feuer E; de Koning HJ; Cronin KA
Ann Intern Med; 2016 Feb; 164(4):215-25. PubMed ID: 26756606
[TBL] [Abstract][Full Text] [Related]
5. Polygenic risk scores for the prediction of common cancers in East Asians: A population-based prospective cohort study.
Ho PJ; Tan IB; Chong DQ; Khor CC; Yuan JM; Koh WP; Dorajoo R; Li J
Elife; 2023 Mar; 12():. PubMed ID: 36971353
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification.
Olsen M; Fischer K; Bossuyt PM; Goetghebeur E
BMC Cancer; 2021 Dec; 21(1):1351. PubMed ID: 34930164
[TBL] [Abstract][Full Text] [Related]
7. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
8. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
Hofvind S; Holen ÅS; Aase HS; Houssami N; Sebuødegård S; Moger TA; Haldorsen IS; Akslen LA
Lancet Oncol; 2019 Jun; 20(6):795-805. PubMed ID: 31078459
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
Mital S; Nguyen HV
BMC Cancer; 2022 May; 22(1):501. PubMed ID: 35524200
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.
Evans DGR; Harkness EF; Brentnall AR; van Veen EM; Astley SM; Byers H; Sampson S; Southworth J; Stavrinos P; Howell SJ; Maxwell AJ; Howell A; Newman WG; Cuzick J
Breast Cancer Res Treat; 2019 Jul; 176(1):141-148. PubMed ID: 30941651
[TBL] [Abstract][Full Text] [Related]
11. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
[TBL] [Abstract][Full Text] [Related]
12. Benefits and harms of polygenic risk scores in organised cancer screening programmes: a cost-effectiveness analysis.
Xia C; Xu Y; Li H; He S; Chen W
Lancet Reg Health West Pac; 2024 Mar; 44():101012. PubMed ID: 38304718
[TBL] [Abstract][Full Text] [Related]
13. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
14. Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2007; 7(1):1-32. PubMed ID: 23074501
[TBL] [Abstract][Full Text] [Related]
15. The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme--a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone.
Gilbert FJ; Tucker L; Gillan MG; Willsher P; Cooke J; Duncan KA; Michell MJ; Dobson HM; Lim YY; Purushothaman H; Strudley C; Astley SM; Morrish O; Young KC; Duffy SW
Health Technol Assess; 2015 Jan; 19(4):i-xxv, 1-136. PubMed ID: 25599513
[TBL] [Abstract][Full Text] [Related]
16. Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.
Nickson C; Procopio P; Velentzis LS; Carr S; Devereux L; Mann GB; James P; Lee G; Wellard C; Campbell I
Breast Cancer Res; 2018 Dec; 20(1):155. PubMed ID: 30572910
[TBL] [Abstract][Full Text] [Related]
17. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial.
Miller AB; Wall C; Baines CJ; Sun P; To T; Narod SA
BMJ; 2014 Feb; 348():g366. PubMed ID: 24519768
[TBL] [Abstract][Full Text] [Related]
18. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers.
Li J; Holm J; Bergh J; Eriksson M; Darabi H; Lindström LS; Törnberg S; Hall P; Czene K
Ann Oncol; 2015 Mar; 26(3):517-22. PubMed ID: 25488685
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
